Optimization Of Splice Switching Therapies To Treat Duchenne Muscular Dystrophy
Funder
National Health and Medical Research Council
Funding Amount
$448,827.00
Summary
Duchenne muscular dystrophy, the most common and serious form of childhood muscle wasting, is caused by mutations in the dystrophin gene that block synthesis of the normal product. Antisense oligomers have been used in clinical trials to remove the disease-causing part of the message and rescue expression. Clinical trials have demonstrated proof-of-concept, although individual responses varied. This application seeks to improve the therapeutic potential of these compounds.
Improving Global Tuberculosis Control With The AuTuMN Platform
Funder
National Health and Medical Research Council
Funding Amount
$655,059.00
Summary
Tuberculosis (TB) is the world’s leading infectious killer, with the failure of global control responsible for the vast majority of Australia’s cases. Using our robustly developed software platform, we have performed several country-level studies to predict the future burden of disease and compare the impact of alternative responses to controlling the epidemic. In this project, we will extend our platform to perform simulations at the global level and answer key questions in TB control.
Novel Dual Domain Targeting Strategies Against ErbB Receptors
Funder
National Health and Medical Research Council
Funding Amount
$711,216.00
Summary
This project will develop innovative strategies to treat cancer through novel antibodies to erbB growth factor receptors, and identify ways to improve conventional treatments.
Design And Delivery Of Peptide-based Anti-cancer Grb7 Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$603,126.00
Summary
The Grb7 protein is overproduced in many types of cancer cells and plays a role in cancer cell growth and spread. The current proposal builds upon the discovery of a peptide-based Grb7 inhibitor that has anti-cancer activity. This proposal is to prepare more potent inhibitor molecules that can efficiently reach the target cancer cells. Such molecules will be used for the study of Grb7 and for the development of a new Grb7-based anti-cancer drug therapy.
IPrevent: Development And Pilot Testing Of An Evidence-based, Tailored, Computerised Risk Assessment And Decision Support Tool To Facilitate Discussions About Breast Cancer Prevention And Screening Measures.
Funder
National Health and Medical Research Council
Funding Amount
$415,143.00
Summary
Women at increased risk for breast cancer should be identified and offered prevention and intensified screening. Yet most women don’t know their personal risk for breast cancer. We will develop a user friendly, computerised tool which, used with her doctor, will help each woman understand her personal breast cancer risk and the benefits and disadvantages of prevention and screening strategies. It will empower women to understand and take control of their breast cancer risk.
Targeting The Plasmodium Falciparum Metalloaminopeptidases For Development Of New Antimalarial Agents
Funder
National Health and Medical Research Council
Funding Amount
$565,507.00
Summary
Each year 1-2 million people will die from malaria. The prevention and treatment of malaria is becoming increasingly difficult due to the spread of drug-resistance. There is an urgent need for next generation of antimalarials with new modes of action. This project will develop new antimalarial agents against the malarial aminopeptidase drug targets.
Enhancing Cognitive Behavioural Treatment Outcomes For Social Phobia
Funder
National Health and Medical Research Council
Funding Amount
$344,129.00
Summary
Social phobia is a serious difficulty that has a tremendous impact in an individual's life. Psychological programs for social phobia have yielded relatively strong positive outcomes, however some individuals do not gain the optimum benefit from these programs. This study aims to test the effectiveness of an added component in the treatment for social phobia which focuses on increasing engagement with treatment in order to optimise outcomes.
Clinical Outcomes With Electroconvulsive Therapy: Insights From Computational Modelling
Funder
National Health and Medical Research Council
Funding Amount
$347,767.00
Summary
Electroconvulsive therapy (ECT) is the treatment of choice for severe, resistant depression. However it use is reduced by concerns about memory problems. The effectiveness and side effects of ECT depend on how it is given, but clinical trials can only test 1 variation at a time. This study will use sophisticated computational modelling to understand how varying the treatment approach affects clinical outcomes, allowing the development of next-generation, custom-designed ECT treatment.
A Randomised Open-label Study Comparing The Safety And Efficacy Of Two Alternative Treatment Options In The Management Of HIV-1 Infected Participants Who Have Virologically Failed A Standard First-line Combination ART Regimen
Funder
National Health and Medical Research Council
Funding Amount
$457,676.00
Summary
For the past decade there has been an unprecedented international effort to provide access to care for all HIV-infected people as a basic human right. Most of these people are treated with a simple combination of drugs that are well proven to control HIV. However, what to do when this first drug combination stops working is unknown. This study aims to fill that knowledge gap so that patients failing the first drug combination can be offered a second combination with a maximal chance of success.
A New Class Of Anti-Malarial Agents Targetting Apical Membrane Antigen
Funder
National Health and Medical Research Council
Funding Amount
$597,598.00
Summary
Malaria is a major global health problem that imposes a substantial burden on the world’s most vulnerable societies. The invasion of host cells by malaria parasites represents an attractive target for therapeutic intervention, and Apical Membrane Antigen 1 (AMA1) plays an essential role in this process. Agents that bind to a key interaction site on AMA1 prevent host cell invasion and thus represent starting points for the development of a new class of anti-malarial drugs.